REVIEW PAPER
Liver metabolic diseases presenting with liver enlargement
Publication date: 2018-06-07
Pediatr Pol 2018;93(2):165-179
KEYWORDS
lysosomal acid lipase deficiencyGaucher diseaseNiemann-Pick diseaseglycogen storage disordersgangliosidosesmucopolisaccharidosescongenital disorders of glycosylation
ABSTRACT
The article constitutes a review of clinical manifestations, laboratory abnormalities, and diagnostics of liver metabolic diseases presenting with hepatomegaly.
REFERENCES (54)
1.
Wolf AD, Lavine JE. Hepatomegaly in neonates and children. Ped Rev 2000; 21: 303-310.
2.
Pawłowska J, Klaudel-Dreszler M, Tylki-Szymańska A. Hepato- i splenoemgalia. W: Socha P, Lebensztejn D, Kamińska D (red.). Gastroenterologia dziecięca – podręcznik do specjalizacji. Wydawnictwo Media-Press Sp. z o.o., Warszawa 2016: 213-217.
3.
Tylki-Szymanska A, Wamelink MMC, Stradomska TJ i wsp. Clinical and molecular characteristics of two transaldolase-deficient patients. Eur J Pediatr 2014; 173: 1679-1682.
4.
Banne E, Meiner V, Shaag A i wsp. Transaldolase Deficiency: A New Case Expands the Phenotypic Spectrum. JIMD Rep 2016; 26: 31-36.
5.
Tylki-Szymańska A, Stradomska TJ, Wamelink MM i wsp. Transaldolase deficiency in two new patients with a relative mild phenotype. Mol Genet Metab 2009; 97: 15-17.
6.
Loeffen YG, Biebuyck N, Wamelink MM i wsp. Nephrological abnormalities in patients with transaldolase deficiency. Nephrol Dial Transplant 2012; 27: 3224-3227.
7.
Vanier MT, Latour P. Laboratory diagnosis of Niemann-Pick disease type C: the filipin staining test. Methods Cell Biol 2015; 126: 357-375.
8.
Polo G, Burlina A, Furlan F i wsp. High level of oxysterols in neonatal cholestasis: a pitfall in analysis of biochemical markers for Niemann-Pick type C disease. Clin Chem Lab Med 2016; 54: 1221-1229.
9.
Patterson MC, Hendriksz CJ, Walterfang M i wsp. Recommendations for the diagnosis and management of Niemann-Pick disease type C: an update. Mol Genet Metab 2012; 106: 330-344.
11.
Vanier MT, Gissen P, Bauer P i wsp. Diagnostic tests for Niemann-Pick disease type C: a critical review. Mol Genet Metabol 2016; 118: 244-254.
12.
Surmeli-Onay O, Yakarisik S, Korkmaz A i wsp. Prenatal-Onset Niemann-Pick Type C Disease with Nonimmune Hydrops Fetalis. Ped and Neonatol 2013; 54: 344-347.
13.
Spiegel R, Raas-Rothschild A, Reish O i wsp. The clinical spectrum of fetal Niemann-Pick type C. Am J Med Genet 2009; 149A: 446-450.
14.
Valayonnopoulos V, Verhoeven NM, Mention K i wsp. Transaldolase deficiency: a new cause of hydrops fetalis and neonatal multi-organ disease. Pediatrics 2006; 149: 713-717.
15.
LeDuc CA, Crouch EE, Wilson A i wsp. Novel association of early onset hepatocellular carcinoma with transaldolase deficiency. JIMD Rep 2014; 12: 121-127.
16.
Andrade-Campos M, Alfonso P, Irun P i wsp. Diagnosis features of pediatric Gaucher disease patients in the era of enzymatic therapy, a national-base study from the Spanish Registry of Gaucher Disease. Orphanet J Rare Dis 2017; 12: 84.
17.
Raskovalova T, Deegan PB, Yang R i wsp. Plasma chitotriosidase activity versus CCL18 level for assessing type I Gaucher disease severity: protocol for a systematic review with meta-analysis of individual participant data. Syst Rev 2017; 6: 87.
18.
Baris HN, Cohen IJ, Mistry PK. Gaucher Disease: The Metabolic Defect, Pathophysiology, Phenotypes And Natural History. Pediatr Endocrinol Rev 2014; 12: 72-81.
19.
Stirnemann J, Belmatoug N, Camou F i wsp. A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments. Int J Mol Sci 2017; 18: e441.
20.
Cox TM. Gaucher disease: clinical profile and therapeutic developments. Biologics 2010; 4: 299-313.
22.
Weiss K, Gonzalez A, Lopez G i wsp. The Clinical Management of Type 2 Gaucher Disease. Mol Genet Metab 2015; 114: 110-122.
23.
Nalysnyk L, Rotella P, Simeone JC i wsp. Gaucher disease epidemiology and natural history: a comprehensive review of the literature. Hematol 2017; 22: 65-73.
24.
Tylki-Szymańska A, Jurecka A. Lysosomal acid lipase deficiency: Wolman disease and cholesteryl ester storage disease. Pril 2014; 35: 99-106.
25.
Bernstein DL, Hulkova H, Bialer MG i wsp. Cholesteryl ester storage disease: review of the findings of 135 reported patients with an underdiagnosed disease. J Hepatol 2013; 58: 1230-1243.
26.
Drebber U, Andersen M, Kasper HU i wsp. Severe chronic diarrhea and weight loss in cholesteryl ester storage disease: A case report. World J Gastroenterol 2005; 11: 2364-2366.
27.
Aguisanda F, Thorne N, Zheng W. Targeting Wolman Disease and Cholesteryl Ester Storage Disease: Disease Pathogenesis and Therapeutic Development. Curr Chem Genom Transl Med 2017; 11: 1-18.
28.
Kuranobu N, Murakami J, Okamoto K i wsp. Cholesterol ester storage disease with a novel LIPA mutation (L264P) that presented massive hepatomegaly: A case report. Hepatol Res 2016; 46: 477-482.
29.
Bhattacharya K. Investigation and management of the hepatic glycogen storage diseases. Transl Pediatr 2015; 4: 240-248.
30.
Magoulas PL, El-Hattab AW. Glycogen Storage Disease Type IV. W: Pagon RA, Adam MP, Ardinger HH i wsp. (red.). University of Washington, Seattle 1993-2014.
31.
Goldstein J, Austin S, Kishnani P i wsp. Phosphorylase Kinase Deficiency. W: Pagon RA, Adam MP, Ardinger HH i wsp. (red.). University of Washington, Seattle 1993-2014.
32.
Roscher A, Patel J, Hewson S i wsp. The natural history of glycogen storage disease types VI and IX: Long-term outcome from the largest metabolic center in Canada. Mol Genet Metab 2014; 113: 171-176.
33.
Santer R, Steinmann B, Schaub J. Fanconi-Bickel syndrome – a congenital defect of facilitative glucose transport. Curr Mol Med 2002; 2: 213-227.
34.
Shin YS. Glycogen storage disease: clinical, biochemical, and molecular heterogeneity. Semin Pediatr Neurol 2006; 13: 115-120.
35.
Burda P, Hochuli M. Hepatic glycogen storage disorders: what have we learned in recent years? Curr Opin Clin Nutr Metab Care 2015; 18: 415-421.
36.
Caciotti A, Di Rocco M, Filocamo M i wsp. Type II sialidosis: review of the clinical spectrum and identification of the new splicing defect with chitotriosidase assessment in two patients. J Neurol 2009; 256: 1911-1915.
37.
Mutze U, Burger F, Hoffmann J i wsp. Multigene panel next generation sequencing in a patient with cherry red macular spot: Identification of two novel mutations in NEU1 gene causing sialidosis type 1 associated with mild to unspecific biochemical and enzymatic findings. Mol Genet Metabol Rep 2017; 10: 1-4.
38.
d’Azzo A, Machado E, Annunziata I. Pathogenesis, emerging therapeutic targets and treatment in sialidosis. Expert Opin Orphan Drugs 2015; 3: 491-504.
39.
Brackmann F, Kehrer C, Kustermann W i wsp. Rare variant of GM2 gangliosidosis through activator-protein deficiency. Neuropediatrics 2017; 48: 127-130.
40.
Brunetti-Pierri N, Scaglia F. GM1 gangliosidosis: review of clinical, molecular, and therapeutic aspects. Mol Genet Metabol 2008; 94: 391-396.
41.
Utz JRJ, Crutcher T, Schneider J i wsp. Biomarkers of central nervous system inflammation in infantile and juvenile gangliosidoses. Mol Genet Metabol 2015; 114: 274-280.
42.
Beker-Acay M, Elmas M, Kohen R i wsp. Infantile type Sandhoff disease with striking brain MRI findings and a novel mutation. Pol J Radiol 2016; 81: 86-89.
43.
Kuchar L, Sikora J, Gulinello ME i wsp. Quantitation of plasmatic lysosphingomyelin and lysosphingomyelin-509 for differential screening of Niemann-Pick A/B and C diseases. Anal Biochem 2017; 525: 73-77.
44.
McGovern MM, Avetisyan R, Sanson BJ i wsp. Disease manifestations and burden of illness in patients with acid sphingomyelinase deficiency (ASMD). Orphanet J Rare Dis 2017; 12: 41.
45.
Schuchman EH, Desnick RJ. Types A and B Niemann-Pick disease. Mol Genet Metab 2017; 120: 27-33.
46.
Polo G, Burlina AP, Kolamunnage TB i wsp. Diagnosis of sphingolipidoses: a new simultaneous measurement of lysosphingolipids by LC-MS/MS. Clin Chem Lab Med 2017; 55: 403-414.
47.
Schuchman EH, Wasserstein MP. Types A and B Niemann-Pick Disease. Pediatr Endocrinol Rev 2016; 13 Suppl 1: 674-681.
48.
Khan SA, Peracha H, Ballhausen D i wsp. Epidemiology of mucopolysaccharidoses. Mol Genet Metab 2017; 121: 227-240.
49.
Jurecka A, Ługowska A, Golda A i wsp. Prevalence rates of mucopolysaccharidoses in Poland. J Appl Genet 2015; 56: 205-210.
50.
Marques-da-Silva D, Dos Reis Ferreira V, Monticelli M i wsp. Liver involvement in congenital disorders of glycosylation (CDG). A systematic review of the literature. J Inherit Metab Dis 2017; 40: 195-207.
51.
Shanti B, Silink M, Bhattacharya K i wsp. Congenital disorder of glycosylation type Ia: heterogeneity in the clinical presentation from multivisceral failure to hyperinsulinaemic hypoglycaemia as leading symptoms in three infants with phosphomannomutase deficiency. J Inherit Metab Dis 2009; 32: S241-251.
52.
Damen G, de Klerk H, Huijmans J i wsp. Gastrointestinal and other clinical manifestations in 17 children with congenital disorders of glycosylation type Ia, Ib, and Ic. J Pediatr Gastroenterol Nutr 2004; 38: 282-287.
53.
de Lonlay P, Seta N, Barrot S i wsp. A broad spectrum of clinical presentations in congenital disorders of glycosylation I: a series of 26 cases. J Med Genet 2001; 38: 14-19.
54.
Janssen MC, de Kleine RH, van den Berg AP i wsp. Successful liver transplantation and long-term follow-up in a patient with MPI-CDG. Pediatrics 2014; 134: e279-283.
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
